Family Medicine Doctors in Hewitt, TX Accepting Medicare

4 Family Medicine doctors found. Showing 1 - 4

Dr. James Glenn Sharp, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 510 N Hewitt Dr, Hewitt, TX 76643 Phone: 254-420-5000

Dr. Edward A. Cooney, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 510 N Hewitt Dr, Hewitt, TX 76643 Phone: 254-666-3666

Dr. Patrick B. Partin, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 510 N Hewitt Dr, Hewitt, TX 76643 Phone: 254-420-5000

Maria Adelaida Otazo, M.A., M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 510 N Hewitt Dr, Hewitt, TX 76643 Phone: 254-420-5000

News Archive

New guidelines can help fertility practitioners build stronger patient relationships

Pregnantish, the infertility community and content site, has crafted powerful new relationship guidelines to help fertility practitioners build stronger patient relationships, using simple communication tools designed to make every interaction count.

RiskMetrics questions Novartis merger proposal

The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.

Lef1 gene restricts formation of cancer stem cell niches to suppress colorectal tumor growth

The new research findings help to understand mechanisms that lead to different types of intestinal tumors. They show that the Lef1 gene suppresses the development and growth of colorectal cancer by restricting the formation of cancer stem cell niches.

Phase I study results of Pharmacyclics' PCI-32765 Btk inhibitor for B cell NHL presented at ASCO

Pharmacyclics, Inc. today announced results from a Phase I study of its novel orally administered Bruton's tyrosine kinase (Btk) inhibitor, PCI-32765, in patients with relapsed or refractory B cell non-Hodgkin's lymphoma (NHL) including chronic lymphocytic leukemia (CLL) and Waldenstroms Macroglobulinemia (WM). These data are being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place this week in Chicago, IL.

Read more Medical News

› Verified 1 days ago